好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cortical Hypometabolism and Limbic/Paralimbic Hypermetabolic Activity in Multiple Sclerosis: A [F-18]FDG-PET Study
Multiple Sclerosis
P9 - Poster Session 9 (5:00 PM-6:00 PM)
19-007

To identify regional variations in patterns of glucose metabolic activity across neocortical and limbic/paralimbic brain regions in individuals with multiple sclerosis (IwMS) and compare with a control dataset.

In MS, regional brain [F-18]Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) signal may reflect the balance of inflammation, demyelination, neuronal dysfunction, neurodegeneration and network effects. Widespread hypometabolism has been previously reported in MS but heterogeneity in glucose metabolism across brain regions has not been thoroughly evaluated. We have previously identified increased microglial activation in limbic/paralimbic regions in MS but its relationship with regional brain metabolism is not known.

Clinical brain FDG-PET scans conducted in 6 IwMS (mean age: 53.7±16.6 years and median EDSS: 6.0) and 8 age-and sex-matched controls without known neurologic disease were retrospectively evaluated. PET scans were co-registered to standard Montreal Neurological Institute atlas space and segmented using the automated anatomic labeling atlas. Globally-normalized standardized-uptake-value ratios (SUVRs) were calculated and compared between IwMS and controls. P-value<0.05 was considered statistically significant.

In IwMS, there was reduced FDG uptake in neocortical regions including superior and inferior parietal lobe (1.07±0.03 vs 1.17±0.03, p=0.00017), angular gyrus (1.09±0.05 vs 1.21±0.04, p=0.0017), Heschl’s gyrus (1.12±0.03 vs 1.22±0.07, p=0.004), and superior frontal cortex (1.02±0.04 vs1.06±0.02, p=0.04), and increased FDG uptake in limbic/paralimbic structures including amygdala (0.87±0.06 vs 0.77±0.02, p=0.001), hippocampus (0.78±0.05 vs 0.72±0.02, p=0.02), and parahippocampal gyrus (0.85±0.07 vs 0.77±0.02, p=0.01), as compared to controls. Other regions with significant hypermetabolism in IwMS were selected regions of cerebellum and vermis, pons, putamen, and olfactory and fusiform gyri (all p<0.05).

Neocortical hypometabolism and limbic/paralimbic hypermetabolism suggest regionally heterogeneous dysmetabolic patterns in IwMS. Limbic/paralimbic hypermetabolism may be related to microglial activation previously observed in these regions. Further studies are needed to evaluate regional FDG-PET changes in different stages of MS and their relationship with neuroinflammation and response to current and emerging MS therapies.

Authors/Disclosures
Moogeh Baharnoori (Kingston General Hospital)
PRESENTER
Dr. Baharnoori has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Baharnoori has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme . Dr. Baharnoori has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Baharnoori has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD serono. Dr. Baharnoori has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Baharnoori has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Baharnoori has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Baharnoori has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis . Dr. Baharnoori has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb.
Steven Cicero, BS (Brigham and Women's Hospital) Steven Cicero has nothing to disclose.
Nicolas Horan Mr. Horan has nothing to disclose.
Shipra Dubey Shipra Dubey has nothing to disclose.
Marie Kijewski (Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115) No disclosure on file
Bonnie Glanz (Brigham and Women'S Hospital) The institution of Ms. Glanz has received research support from CMSC. The institution of Ms. Glanz has received research support from NIH.
Jonathan D. Zurawski, MD (Brigham & Women's Hospital) The institution of Dr. Zurawski has received research support from The Race to Erase MS Foundation. The institution of Dr. Zurawski has received research support from Novartis Pharmaceuticals. The institution of Dr. Zurawski has received research support from I-Mab Biopharma . The institution of Dr. Zurawski has received research support from Elizabeth A. Kremer MS Research Foundation. The institution of Dr. Zurawski has received research support from Novartis.
Howard L. Weiner, MD (Brigham and Women'S Hospital) Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..
Tarun Singhal, MD (Brigham And Women's Hospital) Dr. Singhal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Singhal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech . Dr. Singhal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Singhal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Singhal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme Sanofi. Dr. Singhal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana LifeSciences. The institution of Dr. Singhal has received research support from Novartis. The institution of Dr. Singhal has received research support from Department of Defense. The institution of Dr. Singhal has received research support from Foundation for Neurologic Diseases.